TCIM
OCUL icon

TIAA CREF Investment Management’s Ocular Therapeutix OCUL Stock Holding History

TIAA CREF Investment Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$236K Sell
59,473
-20,930
-26% -$84.1K ﹤0.01% 2854
2018
Q4 		$320K Buy
80,403
+20,930
+35% +$115K ﹤0.01% 2750
2018
Q3 		$409K Sell
59,473
-2,470
-4% -$15.5K ﹤0.01% 2798
2018
Q2 		$418K Sell
61,943
-9,144
-13% -$62.8K ﹤0.01% 2855
2018
Q1 		$463K Buy
71,087
+18,736
+36% +$105K ﹤0.01% 2771
2017
Q4 		$233K Sell
52,351
-3,368
-6% -$17.2K ﹤0.01% 2986
2017
Q3 		$344K Sell
55,719
-55,300
-50% -$356K ﹤0.01% 2970
2017
Q2 		$1.03M Buy
111,019
+785
+0.7% +$7.6K ﹤0.01% 2531
2017
Q1 		$1.02M Buy
110,234
+34,449
+45% +$287K ﹤0.01% 2492
2016
Q4 		$634K Sell
75,785
-1,150
-1% -$8.92K ﹤0.01% 2750
2016
Q3 		$529 Hold
76,935
– – ﹤0.01% 2827
2016
Q2 		$381K Buy
76,935
+28,467
+59% +$282K ﹤0.01% 2969
2016
Q1 		$468K Hold
48,468
– – ﹤0.01% 2805
2015
Q4 		$454K Sell
48,468
-9,504
-16% -$103K ﹤0.01% 2921
2015
Q3 		$815K Buy
57,972
+5,879
+11% +$118K ﹤0.01% 2689
2015
Q2 		$1.1M Buy
52,093
+29,910
+135% +$741K ﹤0.01% 2647
2015
Q1 		$931K Buy
22,183
+10,154
+84% +$334K ﹤0.01% 2654
2014
Q4 		$283K Buy
12,029
+1,490
+14% +$25.1K ﹤0.01% 3063
2014
Q3 		$158K Buy
+10,539
New +$156K ﹤0.01% 3097

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

TIAA CREF Investment Management's OCUL Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Ocular Therapeutix (OCUL) stake by 26% in Q1 2019, selling an estimated $84.1K and leaving 59,473 shares worth $236K. The position accounts for ﹤0.01% of the portfolio, ranked #2854.

TIAA CREF Investment Management first reported a position in OCUL in Q3 2014 and has held it in 19 quarters since. The position peaked at $1.1M in Q2 2015. 68 funds tracked by Wall St. Rank hold OCUL as of Q1 2019.

  • TIAA CREF Investment Management held 59,473 shares of Ocular Therapeutix worth $236K as of Q1 2019.
  • TIAA CREF Investment Management sold 20,930 Ocular Therapeutix shares in Q1 2019, an estimated $84.1K.
  • Ocular Therapeutix made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2854 holding.
  • TIAA CREF Investment Management first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 19 quarters since.
  • TIAA CREF Investment Management's Ocular Therapeutix position peaked at $1.1M in Q2 2015.
  • 68 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.